Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
CBIO compared with DMRA: revenue, margins and what each company keeps, and the suppliers and customers both name
CBIO
Crescent Biopharma, Inc.
Change
Mkt cap
Revenue
Revenue
DMRA
Damora Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
CBIO
Crescent Biopharma, Inc.
vs
DMRA
Damora Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
CBIO
1 of 4 reports
Report
implied
realized
× implied
Q2 FY26
—
▲
+1.69%
—
DMRA
No earnings history for DMRA.
= implied
CBIO realized, solid
DMRA realized, hatched
One scale, both sides: full bar = 2%
× = |realized| ÷ implied
Source: market data
CBIO
Crescent Biopharma, Inc.
Change
13.80
▲
+6.68%
· post 13.28
Mkt cap
$502.9M
Revenue
$1M
Q1 FY26
DMRA
Damora Therapeutics, Inc.
Change
23.56
▲
+7.78%
· post 23.56
Closed
Nov 6 '26
Mkt cap
$1.5B
Revenue
—
vs
Compare
Closed
Nov 6 '26
CBIO
Crescent Biopharma, Inc.
vs
DMRA
Damora Therapeutics, Inc.
13.80
▲
+6.68%
post 13.28
Price
23.56
▲
+7.78%
post 23.56
$502.9M
Mkt cap
$1.5B
Q1 FY26
$1M
Revenue
—
Change
Change
CBIO
13.80
▲
+6.68%
vs
DMRA
23.56
▲
+7.78%
Closed
Nov 6 '26